Hospital

The phase 3 clinical program, CORALreef, consists of 3 trials and is likely the first of its kind for an oral PCSK9 inhibitor, according to the study authors.

The opioid settlement framework could have a significant impact on the future of cannabis distribution and its role in health care.

Investigators will continue to research RBX2660 in patients who are immunocompromised or who have chronic conditions with Clostridioides difficile infection.

Despite study findings showing that 1 in 5 patients hospitalized for COVID-19 developed persistent high blood pressure, many had underlying risk factors.

Patients with cancer and survivors of cancer that had engaged in administrative tasks to effectively estimate costs or pay for care was associated with an 18% increase in cost-related treatment delays or treatment nonadherence.

Nirsevimab (Beyfortus) is the first respiratory syncytial virus (RSV) preventative drug to be approved by the FDA, and can protect infants through their first RSV season for up to 5 months.

Pharmacists can actively engage in the implementation of the Comprehensive Diagnostics and Examinations in Acute Coronary Syndromes pathway within the hospital or health care system.

Technology and regulations can revolutionize drug manufacturing and ensure a stable supply of medications.

The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.

The kinase inhibitor is already approved for patients who experienced recurrence following 1 or more lines of standard of care platinum-containing chemotherapy.

Luspatercept-aamt (Reblozyl) approved to treat adults with very low- to intermediate-risk myelodysplastic syndrome who may require regular red blood cell transfusions.

This technique may be applied to transdermal applications, such as shot-free vaccines.

The start date of the package-level electronic tracking system will shift from November 27, 2023 to November 27, 2024.

Advanced technology can automate many pharmacovigilance tasks to build workflow efficiencies, reduce manual intervention, and free up team members for more strategic activities.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

Pharmacists' expertise is invaluable to prescribers who are unfamiliar with opioid use disorder treatment protocols.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

With the help of new and complex algorithms and self-learning models, we are currently privy to what we may look back on as the golden era of AI.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.

Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients.

Investigators determined that there needs to be an evaluation of harm caused by pharmacy professionals who are in unique positions on social media, propagating misinformation about COVID-19, vaccines, treatment, masks, and other conspiracy theories.

Participants indicated that they would be more likely to accept PrEP-related information if it was recommended by a trusted person.

The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.

Belzutifan also demonstrated statistically significant improvements in objective response rate compared to everolimus for advanced renal cell carcinoma.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.